Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round includes participation from new investor ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday. The terms of the IPO were not ...

Now, Shift, a new social venture founded by Dutch entrepreneur ... Supported by a network of Dutch strategic partners and impact financiers, the first Shift landmark will be in the Netherlands ...

The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a ...

JPMorgan event follows the murder of an industry leader and the nomination of a vaccine sceptic as top official ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...